Skip to main content

Our Impact

Our Impact

See how our high-quality academic work is benefitting people across the globe.

Changing the world for the better

  • A new technique to prevent transmission of mitochondrial disease 
  • Approval of eculizumab and establishment of a national service to treat patients with Atypical Haemolytic Uraemic Syndrome
  • Ataluren: the first approved oral treatment for Duchenne muscular dystrophy
  • Human-derived limbal cell transplant to treat chemical burns of the eye
  • Erdafitinib, the first-in-class treatment of bladder cancer
  • Fibrofind, a stable human alternative for testing anti-fibrotic drugs
  • Aspirin to decrease the risk of colorectal cancer for patients with Lynch syndrome
  • Peptest, a quick and simple test for reflux
  • Skimune, a test for adverse immune reactions to compounds including chemical cosmetics and novel pharmaceuticals
Hyperfused mitochondria and DNA

Spin Out Companies

We have an excellent track record for producing spin out companies from applied research with a significant role in the development of new products and services. Spin out companies also contribute to the development and vitality of the region through new jobs and revenue creation.